Insmed Incorporated (NASDAQ:INSM) Shares Sold by Man Group plc

Man Group plc trimmed its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 95.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,963 shares of the biopharmaceutical company's stock after selling 586,983 shares during the quarter. Man Group plc's holdings in Insmed were worth $2,000,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. NWI Management LP grew its stake in Insmed by 186.0% during the 4th quarter. NWI Management LP now owns 279,000 shares of the biopharmaceutical company's stock worth $19,262,000 after purchasing an additional 181,460 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Insmed by 19.4% during the 4th quarter. Nuveen Asset Management LLC now owns 1,266,630 shares of the biopharmaceutical company's stock worth $87,448,000 after purchasing an additional 205,473 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Insmed during the 4th quarter worth $6,528,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Insmed by 10.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 105,313 shares of the biopharmaceutical company's stock worth $7,270,000 after purchasing an additional 10,352 shares during the last quarter. Finally, Ensign Peak Advisors Inc lifted its position in shares of Insmed by 9.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 529,049 shares of the biopharmaceutical company's stock worth $36,526,000 after purchasing an additional 44,928 shares during the last quarter.

Insmed Stock Performance

Shares of NASDAQ:INSM traded down $1.43 on Wednesday, reaching $66.59. The company's stock had a trading volume of 1,354,220 shares, compared to its average volume of 2,331,008. The stock's 50-day moving average is $70.24 and its two-hundred day moving average is $72.99. Insmed Incorporated has a 52-week low of $44.51 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $12.13 billion, a P/E ratio of -11.91 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same period in the previous year, the company posted ($1.06) earnings per share. Insmed's quarterly revenue was up 22.9% on a year-over-year basis. As a group, sell-side analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at $25,996,328.94. The trade was a 5.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Clarissa Desjardins purchased 1,130 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were purchased at an average price of $66.35 per share, for a total transaction of $74,975.50. Following the completion of the purchase, the director now owns 3,025 shares of the company's stock, valued at approximately $200,708.75. This trade represents a 59.63% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 153,098 shares of company stock valued at $10,724,192. Insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INSM. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. Truist Financial lifted their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. Finally, Jefferies Financial Group began coverage on shares of Insmed in a research report on Tuesday, May 13th. They set a "buy" rating and a $105.00 price objective for the company. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat, Insmed has a consensus rating of "Moderate Buy" and a consensus target price of $94.63.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.